Effects of Dietary Supplementation with a Ferulic Acid-Rich Bioactive Component of Wheat Bran in a Murine Model of Graft-Versus-Host Disease

被引:0
|
作者
Preciado, Silvia [1 ,2 ,3 ]
Martinez-Villaluenga, Cristina [4 ]
Rico, Daniel [5 ]
Muntion, Sandra [1 ,2 ,3 ]
Garcia-Macias, Maria-Carmen [6 ,7 ]
Navarro-Bailon, Almudena [1 ,2 ,3 ]
Martin-Diana, Ana Belen [5 ]
Sanchez-Guijo, Fermin [1 ,2 ,3 ]
机构
[1] Univ Salamanca, Univ Hosp Salamanca, Inst Invest Biomed Salamanca IBSAL, Hematol Dept,Cell Therapy Unit, Salamanca 37007, Spain
[2] ISCIII, RICORS TERAV, Madrid 28029, Spain
[3] Ctr Red Med Regenerat & Terapia Celular Castilla &, Salamanca 37007, Spain
[4] CSIC, Inst Food Sci Technol & Nutr ICTAN, Jose Antonio Novais 10, Madrid 28040, Spain
[5] Agr Technol Inst Castilla & Leon ITACyL, Ctra Burgos Km 119, Valladolid 47071, Spain
[6] Univ Salamanca, Dept Med, Salamanca 37007, Spain
[7] Univ Salamanca, Canc Res Ctr, Salamanca 37007, Spain
关键词
wheat bran; ferulic acid; graft-versus-host disease; anti-inflammatory activity; immunomodulation; mouse model; MESENCHYMAL STEM-CELLS; PATHWAYS;
D O I
10.3390/nu15214582
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Graft-versus-host disease (GvHD) is a common and severe complication following allogeneic hematopoietic stem cell transplantation (HSCT). Its prevention and treatment is a major challenge. Ferulic acid (FA) has anti-inflammatory and antioxidant properties that could be attractive in this setting. Our aim was to evaluate a bioactive ingredient derived from wheat bran (WB), selected for its high concentration of FA, in a murine model of GvHD. The ingredient was obtained via a bioprocess involving hydrolysis and spray-drying. GvHD was induced via HSCT between MHC-mismatched mouse strains. FA treatment was administered orally. Survival and disease scores (weight loss, hunching, activity, fur texture, and skin integrity, each scored between 0 and 2 depending on disease severity) were recorded daily, histological evaluation was performed at the end of the experiment, and serum inflammatory cytokines were analyzed on days 9 and 28. Treatment with FA did not protect GvHD mice from death, nor did it diminish GvHD scores. However, histological analysis showed that ulcers with large areas of inflammatory cells, vessels, and keratin were less common in skin samples from FA-treated mice. Areas of intense inflammatory response were also seen in fewer small intestine samples from treated mice. In addition, a slight decrease in INF-gamma and TNF-alpha expression was observed in the serum of treated mice on day 28. The results showed some local effect of the ingredient intervention, but that the dose used may not be sufficient to control or reduce the inflammatory response at the systemic level in mice with GvHD. Higher dosages of FA may have an impact when evaluating the immunomodulatory capabilities of the hydrolyzed WB ingredient. Thus, further experiments and the use of technological strategies that enrich the ingredients in soluble ferulic acid to improve its efficacy in this setting are warranted.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Acute Renal Graft-Versus-Host Disease in a Murine Model of Allogeneic Bone Marrow Transplantation
    Schmid, Peter M.
    Bouazzaoui, Abdellatif
    Schmid, Karin
    Birner, Christoph
    Schach, Christian
    Maier, Lars S.
    Holler, Ernst
    Endemann, Dierk H.
    CELL TRANSPLANTATION, 2017, 26 (08) : 1428 - 1440
  • [22] The role of p53 and Fas in a model of acute murine graft-versus-host disease
    Yada, S
    Takamura, N
    Inagaki-Ohara, K
    O'Leary, MK
    Wasem, C
    Brunner, T
    Green, DR
    Lin, TS
    Pinkoski, MJ
    JOURNAL OF IMMUNOLOGY, 2005, 174 (03): : 1291 - 1297
  • [23] A Novel Murine Model for Lupus-Like Ocular Chronic Graft-Versus-Host Disease
    Sun, Yan
    Zhang, Yue
    Shen, Jiani
    Shi, Fan
    Li, Ye
    Wang, Congyao
    Dong, Xia
    Chen, Tingting
    Yu, Fenfen
    Zhou, Yi
    Wan, Pengxia
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (06)
  • [24] A locus on chromosome 2 influences the development of acute graft-versus-host disease in a murine model
    JM Harper
    DL Slayback
    JA Dobkins
    RD Allen
    Bone Marrow Transplantation, 1999, 23 : 1183 - 1190
  • [25] HISTOPATHOLOGY OF CUTANEOUS GRAFT-VERSUS-HOST DISEASE TO MINOR HISTOCOMPATABILITY ANTIGENS IN A MURINE MODEL SYSTEM
    FERRARA, J
    GUILLEN, FJ
    BURAKOFF, SJ
    MURPHY, GF
    LABORATORY INVESTIGATION, 1985, 52 (01) : A22 - A22
  • [26] IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects
    Liu, Y.
    Wu, Y.
    Wang, Y.
    Cai, Y.
    Hu, B.
    Bao, G.
    Fang, H.
    Zhao, L.
    Ma, S.
    Cheng, Q.
    Song, Y.
    Liu, Y.
    Zhu, Z.
    Chang, H.
    Yu, X.
    Sun, A.
    Zhang, Y.
    Vignali, D. A. A.
    Wu, D.
    Liu, H.
    LEUKEMIA, 2015, 29 (04) : 939 - 946
  • [27] IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects
    Y Liu
    Y Wu
    Y Wang
    Y Cai
    B Hu
    G Bao
    H Fang
    L Zhao
    S Ma
    Q Cheng
    Y Song
    Y Liu
    Z Zhu
    H Chang
    X Yu
    A Sun
    Y Zhang
    D A A Vignali
    D Wu
    H Liu
    Leukemia, 2015, 29 : 939 - 946
  • [28] EFFECTS OF THE AUTOTAXIN INHIBITOR ZIRITAXESTAT ON SKIN AND LUNG FIBROSIS IN A MURINE GRAFT-VERSUS-HOST DISEASE MODEL OF SYSTEMIC SCLEROSIS
    Zhang, Y.
    Summa, L.
    Heckmann, B.
    Distler, J. H. W.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 148 - 149
  • [29] Genetics of graft-versus-host disease, I. A locus on Chromosome 1 influences development of acute graft-versus-host disease in a major histocompatibility complex mismatched murine model
    Allen, RD
    Dobkins, JA
    Harper, JM
    Slayback, DL
    IMMUNOLOGY, 1999, 96 (02) : 254 - 261
  • [30] Effector T cells require fatty acid metabolism during murine graft-versus-host disease
    Byersdorfer, Craig A.
    Tkachev, Victor
    Opipari, Anthony W.
    Goodell, Stefanie
    Swanson, Jacob
    Sandquist, Stacy
    Glick, Gary D.
    Ferrara, James L. M.
    BLOOD, 2013, 122 (18) : 3230 - 3237